The Gut-lung Axis in Chronic Obstructive Pulmonary Disease
Study Details
Study Description
Brief Summary
Patients with chronic obstructive pulmonary disease (COPD) are 2-3 times more likely to occur together with chronic gastrointestinal tract (GIT) diseases, such as inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). Similarly, despite many patients have no history of acute or chronic respiratory disease, up to 50% of IBD patients and 33% of IBS patients have pulmonary involvement, such as inflammation or impaired lung function. Increasing evidence indicated chronic gut and lung disease share key conceptual features with the disorder and dysregulation of the microbial ecosystem. However, the underlying mechanisms are not well understood.
Our study is aimed to elucidate the intimate relationship between the gastrointestinal tract and respiratory tract, and uncover the mechanisms by which the gut microbiota affects the immune responses in the lungs, and vice versa.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| COPD Patients who admitted to Peking Universtiy People's Hospital and Ningde City Hospital between January 2017 and January 2019 with AECOPD will be enrolled |
|
| healthy control People aged over 40, without any chronic respiratory disease or acute respiratory infections in the last 2 weeks, and be willing to participate in the study |
Outcome Measures
Primary Outcome Measures
- all-cause mortality [patients will be followed for 3 months after their remission from hospital]
all-cause death after the enrollment
Secondary Outcome Measures
- exacerbations [during the 3-month follow-up]
exacerbations of COPD
Eligibility Criteria
Criteria
Inclusion Criteria:
-
admitted to hospital with an exacerbation of COPD;
-
with no history of probiotics taken;
-
the duration of antibiotics treatment before enrollment should be less than 72 hours.
Exclusion Criteria:
-
being immunocompromised, including history of glucocorticoid taken for more than 1 month, history of immunosuppressive therapy, history of human immunodeficiency virus (HIV) infection, solid tumor or hematological malignancy;
-
history of long-term nursing home stays;
-
history of recently hospitalized (<90 days).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Peking University People's Hospital | Beijing | Beijing | China | 100044 |
Sponsors and Collaborators
- Peking University People's Hospital
- Ningde City Hospital, Fujian, China
Investigators
- Study Chair: Zhancheng Gao, Pro., Peking University People's Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2109901
- 2016YFC0903800